Disappointing study results for Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) reported disappointing results from two Phase 3 clinical trials investigating FMX101 to treat moderate to severe acne sending the stock price plummeting $3.80 to close at $5.30.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.